Vincerx Pharma Inc VINC Stock Analysis
- PINK
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.02 unchanged at close Nov 6
Last close · Previous close $0.02
- Market cap
- At the Nov 6 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$0.02unchangedFri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.02Nov 5
- Volume1.07KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume959.00Last 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.00 to $0.03; now $0.02
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
VINC beat the S&P 500 in 4 of 6 periods.
| Period | VINC and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | VINC: unchanged S&P 500: down 5.6% | VINC beat the S&P 500 by 5.6 percentage points Beat |
| 3M | VINC: up 18.1% S&P 500: down 4.1% | VINC beat the S&P 500 by 22.2 percentage points Beat |
| YTD | VINC: up 20.0% S&P 500: up 8.7% | VINC beat the S&P 500 by 11.3 percentage points Beat |
| 1Y | VINC: up 183.0% S&P 500: up 10.9% | VINC beat the S&P 500 by 172.1 percentage points Beat |
| Long term | ||
| 3Y | VINC: down 99.9% S&P 500: up 75.0% −90.7% vs +20.5% a year | VINC trailed the S&P 500 by 174.9 percentage points Trailed |
| 5Y | VINC: down 100.0% S&P 500: up 67.8% −86.1% vs +10.9% a year | VINC trailed the S&P 500 by 167.8 percentage points Trailed |
$10,000 invested in VINC 5 years ago (Nov 5, 2021) would be worth about $1 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
VINC beat the S&P 500 in 4 of 6 periods.
| Period | VINC and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | VINC: unchanged S&P 500: down 5.6% | VINC beat the S&P 500 by 5.6 percentage points Beat |
| 3M | VINC: up 18.1% S&P 500: down 4.3% | VINC beat the S&P 500 by 22.4 percentage points Beat |
| YTD | VINC: up 20.0% S&P 500: up 7.8% | VINC beat the S&P 500 by 12.2 percentage points Beat |
| 1Y | VINC: up 183.0% S&P 500: up 9.7% | VINC beat the S&P 500 by 173.3 percentage points Beat |
| Long term | ||
| 3Y | VINC: down 99.9% S&P 500: up 68.8% −90.7% vs +19.1% a year | VINC trailed the S&P 500 by 168.7 percentage points Trailed |
| 5Y | VINC: down 100.0% S&P 500: up 56.9% −86.1% vs +9.4% a year | VINC trailed the S&P 500 by 156.9 percentage points Trailed |
$10,000 invested in VINC 5 years ago (Nov 5, 2021) would be worth about $1 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$518.00
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since May 27, 2020.
Stock splits
1
1-for-20 on . Share counts adjust after each split.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q1 FY25, the quarter ended Mar 31, 2025. “Last 12 months” means the four quarters from Apr 1, 2024 to Mar 31, 2025, and balance-sheet figures are as of Mar 31, 2025.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$22.65M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q2 FY23 (Jun 30, 2023) | $0.00 | −$11.55M | Paused See the note under the price. |
| Q3 FY23 (Sep 30, 2023) | $0.00 | −$9.01M | Paused See the note under the price. |
| Q4 FY23 (Dec 31, 2023) | $0.00 | −$4.95M | Paused See the note under the price. |
| Q1 FY24 (Mar 31, 2024) | $0.00 | −$12.43M | Paused See the note under the price. |
| Q2 FY24 (Jun 30, 2024) | $0.00 | −$1.81M | Paused See the note under the price. |
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$7.84M | Paused See the note under the price. |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$7.99M | Paused See the note under the price. |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$5.00M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY20 (Dec 31, 2020) | $0.00 | −$16.62M | Paused See the note under the price. |
| FY21 (Dec 31, 2021) | $0.00 | −$39.31M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $0.00 | −$62.98M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $0.00 | −$40.16M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $0.00 | −$30.07M | Paused See the note under the price. |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$22.84MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$22.84MLast 12 months
- Capital spending$0.00Last 12 months
Shareholder returns
- $21.84MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $4.52MAs of Mar 31, 2025
Cash plus short- and long-term marketable securities on the Mar 31, 2025 balance sheet.
- Total debt$0.00As of Mar 31, 2025
- Net cash$4.52MAs of Mar 31, 2025
- Book value per sharePausedAs of Mar 31, 2025
See the note under the price. - 1.79As of Mar 31, 2025
Current assets divided by current liabilities on the Mar 31, 2025 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.00As of Mar 31, 2025
Total debt divided by shareholders’ equity on the Mar 31, 2025 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −308.7%Last 12 months
Over the last 12 months, Vincerx Pharma lost money: its net loss was 308.7% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −184.2%Last 12 months
Over the last 12 months, Vincerx Pharma’s net loss was 184.2% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Vincerx Pharma Inc
Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company committed to developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. Vincerx’s pipeline consists of a next-generation ADC, VIP943, currently in Phase 1; a small molecule drug conjugate, VIP236, which has completed its Phase 1 study; a CDK9 inhibitor, enitociclib, which has completed a Phase 1 monotherapy study; a preclinical ADC, VIP924; and VersAptx™, a versatile, next-generation bioconjugation platform. Vincerx is based in San Mateo, California, and has a research subsidiary in Monheim, Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- PINK
- Asset type
- Common stock
- Price history since
VINC news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
VINC stock FAQ
What is VINC stock’s price today?
Vincerx Pharma (VINC) traded at $0.02 at the close on , unchanged from the previous close of $0.02. Over the past 52 weeks it has traded between $0.00 and $0.03.
If you invested $1,000 in VINC 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in VINC on would be worth about $0 at the close on , a total return of −100.0%. The same $1,000 would be worth $2,830 if invested one year ago. Past performance doesn’t predict future returns.
Does VINC pay a dividend?
Vincerx Pharma hasn’t paid a dividend in the last twelve months.
What is VINC’s 52-week high and low?
Over the past 52 weeks VINC has traded as low as $0.00 and as high as $0.03. At $0.02 at the close on , it is 41.6% below that high and 7,400.0% above the low.
What is VINC’s all-time high?
VINC’s highest closing price was $518.00 on , adjusted for stock splits. At $0.02 at the close on , it is 100.0% below that record.
Has VINC stock ever split?
Yes, once: 1-for-20 on .
How has VINC stock performed?
Including dividends and measured to the close on , VINC has returned +20.0% so far this year and +183.0% over the past year, and −100.0% over five years (−86.1% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Vincerx Pharma in?
Vincerx Pharma is in the Healthcare sector and the Biotechnology industry, and is headquartered in California, USA.
What exchange does VINC trade on?
Vincerx Pharma trades on the PINK under the ticker symbol VINC. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.